Here are three things to know.
1. The upfront payments were not disclosed, however, Kineta is eligible to receive up to $359 million on top of royalty payments.
2. Genentech has the ability to license technologies developed from the collaborations.
3. Early tests of the drug are displaying disease-modifying effects, such as reduced information and nerve protection.
4. Roche purchased Genentech for $46.8 billion in 2009.
5. Kineta was founded in 2008 to develop drugs for chronic pain, autoimmune and infectious diseases.
More articles on devices and implants:
NovoStitch Pro Meniscal Repair System receives FDA 510(k) clearance: 4 insights
Global spinal fusion devices market to grow at 4.6% CAGR through 2025: 4 observations
Dr. Richard Moore performs 1st surgery with Zimmer Biomet’s Persona Trabecular Metal Tibia: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
